Getting your Trinity Audio player ready...
Halberd Corporation (OTC: HALB) and Mississippi State University (MSU) signed an agreement outlining the testing in pre-clinical models which will be conducted at MSU. The testing will focus on Halberd’s patent-pending nasal spray designed to mitigate the effects of Traumatic Brain Injury (TBI). The work will be conducted under the direction of Dr. Russell Carr, of the College of Veterinary Medicine, as the Principal Investigator.
HALB stock closed up by 6.90% to $0.0155 on Thursday with 1.5X volume its average volume. Moreover, the stock has soared over 29% on increased volume since March 16, 2023
Over the course of the past year or so, Halberd Corporation has been quite busy with its research and development activities and it appears that the company is going to continue on that path for the foreseeable future. Yesterday, the company announced that it signed an agreement with Mississippi State University which outlined the testing in pre-clinical models which would be conducted at the university.
The testing is going to be focussed on the company’s patent-pending nasal spray which is supposed to ameliorate the effects of traumatic brain injury if administered soon after the trauma to the head. The work is going to be conducted from April 10, 2023, and is expected to be concluded on October 10, 2023. The entire project is going to be overseen by Dr. Russell Carr, from the College of Veterinary Medicine, who is going to be the principal investigator.
The Chief Technology Officer of the company Dr. Mitchell S Felder spoke about the unique product from Halberd. He noted that the patent-pending formulation of the nasal spray combined a total of three main ingredients which would work in combination so as to repel the pathophysiologic changes which take place in case of trauma to the brain.
The President and Chief Executive Officer of the company William A Hartman also spoke about the development. He stated that everyone at the company was pleased with this new agreement and was looking forward to a positive outcome at its conclusion.